Etop Ibcsg Partners Foundation

This study tested whether adding the drug bevacizumab to standard treatment (osimertinib) could better control advanced non-small cell lung cancer that had developed a specific resistance mutation. It involved 155 adults whose cancer had progressed after prior targeted therapy. T…

This study tested whether new drug combinations could better control early-stage breast cancer in premenopausal women before surgery. 231 participants received either a new drug called giredestrant, that drug plus a hormone blocker, or a standard hormone therapy for four weeks. R…

This large study tested whether temporarily shutting down the ovaries and adding different hormone-blocking drugs could better prevent breast cancer from returning compared to standard treatment alone. It involved over 3,000 premenopausal women who had surgery for hormone-sensiti…

This large, completed Phase 3 trial tested if a newer hormone therapy combination (exemestane + triptorelin) was better than the standard combination (tamoxifen + triptorelin) at preventing cancer from coming back in premenopausal women with early-stage, hormone-responsive breast…